Please login to the form below

ozanimod

This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.

FDA turns down Celgene’s filing for multiple sclerosis drug

Celgene is facing a delay for its multiple sclerosis candidate ozanimod in the US and elsewhere as the FDA has refused to accept its marketing application for the drug. ... The embarrassing setback has arisen because of deficiencies in the “nonclinical

Latest news

Sanofi licences Principia MS drug in $805m deal

And an even bigger threat is looming in the shape of Celgene’s ozanimod, a once-daily oral therapy that GBI Research has predicted could make rapid headway thanks to a
Celgene pays $300m upfront for immunology start-up Delinia

other pipeline candidates in this therapeutic category including mongersen for inflammatory bowel disease and ozanimod for multiple sclerosis which are both in late-stage testing.
Neurodegenerative disorders market set to reach $45bn by 2022

Among these, are Roche's Ocrevus (ocrelizumab) for multiple sclerosis (MS) and Celgene's ozanimod for relapsed MS, with both firms predicted to become major market players. ... Currently undergoing phase III trials, ozanimod is tipped to become a
Celgene spends $7.2bn on Receptos purchase

The drug, currently known as ozanimod, is undergoing phase III trials for both ulcerative colitis(UC) and relapsing multiple sclerosis (MS). ... Celgene sees peak annual sales of ozanimod hitting between $4bn to $6bn for both conditions.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

Pharma deals in July 2015

Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Project Manager, Medical Communications, London: Excellent Salary

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Account Manager – Med Comms – Kent: Salary TBC

Senior Programme Executive: Salary TBC

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Medical Writer, e-learning/ training, London: Excellent Salary

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Account Manager / Account Director: Great salary and bebefits

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Scientific Director: Great salary and bebefits

Senior Medical Writer: Great salary and bebefits

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Account Manager – Med Comms – London: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Editorial Director – Medical Education – Oxford: Negotiable

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Subscribe to our email news alerts

PMHub

Add my company

Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...